Q&A: How Will Biobetters Fit Into the Growing Biologics Market? Celltrion Executive Explains
August 6th 2022
By The Center for Biosimilars StaffArticle
In an interview with The Center for Biosimilars®, Hyoung Ki Kim, vice chairman and CEO of Celltrion Healthcare, breaks down the benefits of biobetters, how they differ from biosimilars, and how they could alter the future landscape of the biologics industry.